Cagrilintide

Clinical Trials

Cagrilintide

Aliases
CagriSema (combo with semaglutide)
Administration
Subcutaneous injection (once weekly)

Overview

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk, most prominently studied in combination with semaglutide as CagriSema. By mimicking amylin — a hormone co-secreted with insulin that regulates satiety and gastric emptying — it produces additive appetite suppression when paired with GLP-1 agonism.

Treatments studied

Treatment categories

Obesity / weight management

Mimics amylin to add a second, independent layer of appetite suppression beyond GLP-1 alone.

Type 2 diabetes

Studied alongside semaglutide (as CagriSema) for its combined effect on blood sugar and weight.